Abiratred

Abiratred

abiraterone

Manufacturer:

Dr. Reddy's Lab

Distributor:

DKSH
Concise Prescribing Info
Contents
Abiraterone acetate
Indications/Uses
In combination w/ prednisone or prednisolone for metastatic castration resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after docetaxel-based chemotherapy regimen; in asymptomatic or mildly symptomatic adult men after androgen deprivation therapy (ADT) failure in whom chemotherapy is not yet clinically indicated. In combination w/ prednisone or prednisolone & ADT for newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) who may have received up to 3 mth of prior ADT.
Dosage/Direction for Use
mCRPC 1,000 mg as single daily dose w/ prednisone or prednisolone 10 mg daily. mHSPC 1,000 mg as single daily dose w/ prednisone or prednisolone 5 mg daily.
Administration
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals. Swallow whole w/ water.
Contraindications
Hypersensitivity. Combination w/ Ra-223. Severe hepatic impairment (Child-Pugh class C). Women of childbearing potential. Pregnancy.
Special Precautions
Discontinue use if severe hepatotoxicity develops. HTN, hypokalaemia, fluid retention; severe or unstable angina pectoris, recent MI or ventricular arrhythmia; history of CV disease; decreased bone density. Measure serum transaminases prior to, every 2 wk for 1st 3 mth & mthly thereafter. Monitor BP, serum K & fluid retention mthly. Measure blood sugar in diabetic patients frequently. Corticosteroid w/drawal & unusual stress. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Not to be initiated w/ Ra-223 for at least 5 days after last dose. Patients previously treated w/ ketoconazole. Concomitant use w/ cytotoxic chemotherapy. Severe renal & moderate hepatic impairment. Not to be used in severe hepatic impairment. Men & women of childbearing potential should use effective contraception. Not to be used in women.
Adverse Reactions
Peripheral edema; hypokalemia; hypertriglyceridemia; UTI; increased ALT &/or AST; HTN; fractures; cardiac failure, angina pectoris, arrhythmia, atrial fibrillation, tachycardia; hematuria; dyspepsia.
Drug Interactions
Increased absorption w/ food. Avoid use w/ strong CYP3A4 inducers eg, phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarb, St. John's wort. Increased PSA levels w/ spironolactone. Caution w/ drugs prolonging QT interval & inducing Torsade de pointes eg, class IA (eg, quinidine, disopyramide) or III (eg, amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmics, methadone, moxifloxacin, antipsychotics; CYP2D6 & CYP2C8 inhibitors; CYP2D6-metabolised drugs eg, metoprolol, propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone, tramadol.
MIMS Class
Cancer Hormone Therapy
ATC Classification
L02BX03 - abiraterone ; Belongs to the class of other hormone antagonists and related agents. Used in the treatment of metastatic castration-resistant prostate cancer.
Presentation/Packing
Form
Abiratred FC tab 250 mg
Packing/Price
120's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in